BNP Paribas Financial Markets’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$249M Sell
399,847
-48,524
-11% -$33M 0.09% 193
2026
Q1
$346M Buy
448,371
+7,527
+2% +$5.76M 0.17% 115
2025
Q4
$340M Sell
440,844
-36,808
-8% -$25M 0.15% 119
2025
Q3
$269M Sell
477,652
-46,706
-9% -$26.4M 0.14% 120
2025
Q2
$275M Sell
524,358
-222,255
-30% -$124M 0.16% 114
2025
Q1
$474M Buy
746,613
+207,017
+38% +$142M 0.28% 62
2024
Q4
$384M Buy
539,596
+244,184
+83% +$205M 0.22% 80
2024
Q3
$311M Buy
295,412
+48,721
+20% +$54.2M 0.21% 86
2024
Q2
$259M Buy
246,691
+6,867
+3% +$6.66M 0.21% 95
2024
Q1
$231M Buy
239,824
+24,286
+11% +$23.1M 0.2% 101
2023
Q4
$189M Buy
215,538
+30,432
+16% +$25.1M 0.21% 95
2023
Q3
$152M Buy
185,106
+33,903
+22% +$26.6M 0.2% 101
2023
Q2
$109M Buy
151,203
+41,165
+37% +$31.7M 0.14% 146
2023
Q1
$90.4M Buy
110,038
+9,640
+10% +$7.27M 0.13% 157
2022
Q4
$72.4M Buy
100,398
+15,401
+18% +$11.4M 0.11% 211
2022
Q3
$58.6M Sell
84,997
-7,260
-8% -$4.57M 0.09% 239
2022
Q2
$54.5M Buy
92,257
+25,417
+38% +$16.5M 0.09% 261
2022
Q1
$46.7M Sell
66,840
-16,543
-20% -$10.5M 0.06% 302
2021
Q4
$52.7M Buy
83,383
+34,116
+69% +$21M 0.08% 282
2021
Q3
$29.8M Sell
49,267
-31,315
-39% -$19.4M 0.04% 450
2021
Q2
$45M Buy
80,582
+6,611
+9% +$3.35M 0.06% 350
2021
Q1
$35M Sell
73,971
-5,035
-6% -$2.45M 0.05% 371
2020
Q4
$38.2M Sell
79,006
-53,422
-40% -$28.8M 0.07% 279
2020
Q3
$74.1M Buy
132,428
+61,981
+88% +$37.6M 0.11% 183
2020
Q2
$43.9M Sell
70,447
-5,172
-7% -$2.94M 0.08% 234
2020
Q1
$36.9M Buy
75,619
+32,005
+73% +$13.2M 0.08% 241
2019
Q4
$16.4M Sell
43,614
-104,383
-71% -$35.1M 0.03% 573
2019
Q3
$41.1M Sell
147,997
-36,503
-20% -$10.8M 0.07% 265
2019
Q2
$57.7M Buy
184,500
+133,928
+265% +$44.6M 0.12% 192
2019
Q1
$20.8M Sell
50,572
-202,439
-80% -$83.4M 0.04% 421
2018
Q4
$94.5M Sell
253,011
-76,963
-23% -$28.2M 0.22% 97
2018
Q3
$133M Sell
329,974
-13,129
-4% -$5M 0.2% 103
2018
Q2
$118M Sell
343,103
-6,124
-2% -$1.92M 0.2% 103
2018
Q1
$120M Sell
349,227
-146,503
-30% -$51M 0.23% 81
2017
Q4
$186M Buy
495,730
+19,926
+4% +$8.07M 0.33% 55
2017
Q3
$213M Buy
475,804
+50,627
+12% +$24.1M 0.52% 31
2017
Q2
$209M Sell
425,177
-108,066
-20% -$47.3M 0.63% 20
2017
Q1
$207M Buy
533,243
+465,801
+691% +$173M 0.55% 30
2016
Q4
$24.8M Sell
67,442
-1,226
-2% -$466K 0.12% 155
2016
Q3
$27.6M Buy
68,668
+27,576
+67% +$11.1M 0.11% 132
2016
Q2
$14.4M Sell
41,092
-31,483
-43% -$12.1M 0.06% 219
2016
Q1
$26.2M Buy
72,575
+14,285
+25% +$5.89M 0.11% 150
2015
Q4
$31.6M Buy
58,290
+22,798
+64% +$12.4M 0.08% 204
2015
Q3
$16.5M Sell
35,492
-10,222
-22% -$5.49M 0.04% 298
2015
Q2
$23.3M Sell
45,714
-49,975
-52% -$24.4M 0.07% 176
2015
Q1
$43.2M Buy
95,689
+10,158
+12% +$4.3M 0.12% 109
2014
Q4
$35.1M Sell
85,531
-3,605
-4% -$1.42M 0.12% 134
2014
Q3
$32.1M Buy
89,136
+33,004
+59% +$11.1M 0.03% 237
2014
Q2
$15.9M Sell
56,132
-41,537
-43% -$12.3M 0.01% 300
2014
Q1
$29M Sell
97,669
-63,684
-39% -$19.6M 0.02% 221
2013
Q4
$44.4M Buy
161,353
+5,807
+4% +$1.67M 0.03% 180
2013
Q3
$48.7M Buy
155,546
+88,949
+134% +$23.4M 0.04% 187
2013
Q2
$15M Buy
+66,597
New +$15.5M 0.01% 271

Other funds holding REGN

BNP Paribas Financial Markets's REGN Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, selling an estimated $33M and leaving 399,847 shares worth $249M. The position accounts for 0.09% of the portfolio, ranked #193.

BNP Paribas Financial Markets first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $474M in Q1 2025. 1,085 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BNP Paribas Financial Markets held 399,847 shares of Regeneron Pharmaceuticals worth $249M as of Q2 2026.
  • BNP Paribas Financial Markets sold 48,524 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33M.
  • Regeneron Pharmaceuticals made up 0.09% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #193 holding.
  • BNP Paribas Financial Markets first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • BNP Paribas Financial Markets's Regeneron Pharmaceuticals position peaked at $474M in Q1 2025.
  • 1,085 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.